Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • NATURE PODCAST

Coronapod: Ivermectin, what the science says

Noah Baker and Sara Reardon ask why Ivermectin has become such a controversial topic in the pandemic

Ivermectin is a cheap, widely available, anti-parasitic drug that has been proposed by many as a possible treatment for COVID-19. Dozens of trials have been started, but results have been far from clear, with inconsistent results further confused by high profile paper retractions. Nonetheless many countries have recommended the use of Ivermectin, despite WHO advice to the contrary.

Now a group of researchers have found suspect data in another influential paper which claimed a Ivermectin caused a 90% reduction in fatality. The paper, published at the end of 2020, has since been withdrawn pending investigation. In this episode of Coronapod we ask what this might mean for Ivermectin, and what's next for the controversial drug.

Correction: at 2:53 when discussing two discredited studies, we mistakenly say that the papers say "both drugs worked really well". In fact, this retracted study from the Lancet claimed that the drug hydroxychloroquine caused harm. We apologise for any confusion. More information on the scandal surrounding these papers can be found here.

News: Flawed ivermectin preprint highlights challenges of COVID drug studies

News: Latin America’s embrace of an unproven COVID treatment is hindering drug trials

Coronapod: The Surgisphere scandal that rocked coronavirus drug research

Never miss an episode: Subscribe to the Nature Podcast on Apple Podcasts, Google Podcasts, Spotify or your favourite podcast app. Head here for the Nature Podcast RSS feed.

doi: https://doi.org/10.1038/d41586-021-02178-2

Subjects

Nature Careers

Jobs

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing

Search

Quick links